For more than sixty years, ACG has been working to help manufacture oral dosage pharmaceutical and nutraceutical products. From hard shell capsules, to machines and equipment, to barrier packaging materials, to serialisation and traceability solutions, there isn’t much we don’t know about making medicines and supplements.

All our expertise is yours.

When you choose to work with us, all of this expertise is yours: our laboratories are your laboratories; our technical and R&D people are your people; our innovations are your innovations. All over the world.

We understand that being successful in nutra is about more than these things – it’s also about branding and marketing, being first-to-market, and keeping ahead of trends – which is why we have a group business (Vantage Nutrition) dedicated to providing exactly these services too.

Your partner in nutraceuticals.

At ACG we understand the time pressures of the nutraceutical industry, and with a presence in 138 countries, we are equipped to deliver reliably and quickly all over the world. As a privately-owned enterprise, we are also flexible, and value long-term relationships over short-term sales. 

Looking for a real partnership in your nutraceutical venture? Speak to someone who’s willing to invest in your success.

Get in touch

Why work with ACG?

  • 62 years’ experience in pharma and nutra manufacturing on six continents
  • Formulation and R&D resources at your disposal
  • Innovative (and patented) ingredient delivery technologies
  • Complimentary advice and expertise
  • A long-term partnership approach

Explore products

ACG has three global divisions that touch almost every aspect of oral dosage manufacturing. Our holistic view is based on a conviction that this is the best approach to enabling seamless production married with fully accountable service.

Latest news

2023 pharma predictions

Pharma manufacturing

The pandemic continued to affect supply chains, inflation was at a recent all-time high, and FDA approvals hit a five-year low. The Inflation Reduction Act was signed into law back in August, promising to limit the pharma industry’s pricing power.

Read more